CN104755929B - 喹硫平的抗体及其用途 - Google Patents

喹硫平的抗体及其用途 Download PDF

Info

Publication number
CN104755929B
CN104755929B CN201380054983.0A CN201380054983A CN104755929B CN 104755929 B CN104755929 B CN 104755929B CN 201380054983 A CN201380054983 A CN 201380054983A CN 104755929 B CN104755929 B CN 104755929B
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
quetiapine
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380054983.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104755929A (zh
Inventor
E.赫伊霍伦科
B.桑卡兰
T.R.德科里
T.图布斯
L.科特
B.M.雷梅里伊
R.萨特
M.G.多纳胡伊
Y.龚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Ortho Clinical Diagnostics Inc filed Critical Janssen Pharmaceutica NV
Priority to CN201610881661.9A priority Critical patent/CN106928369B/zh
Publication of CN104755929A publication Critical patent/CN104755929A/zh
Application granted granted Critical
Publication of CN104755929B publication Critical patent/CN104755929B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201380054983.0A 2012-08-21 2013-08-20 喹硫平的抗体及其用途 Expired - Fee Related CN104755929B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610881661.9A CN106928369B (zh) 2012-08-21 2013-08-20 喹硫平的抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691659P 2012-08-21 2012-08-21
US61/691659 2012-08-21
PCT/US2013/055834 WO2014031668A2 (en) 2012-08-21 2013-08-20 Antibodies to quetiapine and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610881661.9A Division CN106928369B (zh) 2012-08-21 2013-08-20 喹硫平的抗体及其用途

Publications (2)

Publication Number Publication Date
CN104755929A CN104755929A (zh) 2015-07-01
CN104755929B true CN104755929B (zh) 2016-11-09

Family

ID=50148313

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380054983.0A Expired - Fee Related CN104755929B (zh) 2012-08-21 2013-08-20 喹硫平的抗体及其用途
CN201610881661.9A Expired - Fee Related CN106928369B (zh) 2012-08-21 2013-08-20 喹硫平的抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610881661.9A Expired - Fee Related CN106928369B (zh) 2012-08-21 2013-08-20 喹硫平的抗体及其用途

Country Status (10)

Country Link
US (3) US9410972B2 (https=)
EP (2) EP3333195B1 (https=)
JP (3) JP6242893B2 (https=)
CN (2) CN104755929B (https=)
AU (2) AU2013305907B2 (https=)
CA (1) CA2882615C (https=)
ES (2) ES2654413T3 (https=)
PL (2) PL2888592T3 (https=)
PT (2) PT3333195T (https=)
WO (1) WO2014031668A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837838A (zh) 2012-08-21 2015-08-12 詹森药业有限公司 帕潘立酮半抗原
JP6131414B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールのハプテン及びイムノアッセイにおけるそれらの使用
PL2888592T3 (pl) * 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
WO2014031656A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine haptens and use thereof
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
ES2691092T3 (es) 2012-08-21 2018-11-23 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
JP2015527365A (ja) 2012-08-21 2015-09-17 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンに対する抗体及びその使用
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
JP6450314B2 (ja) * 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
WO2016025494A2 (en) * 2014-08-11 2016-02-18 Ameritox, Ltd. Methods of monitoring adherence to quetiapine therapy
US10517948B2 (en) 2015-03-11 2019-12-31 The Board Of Regents Of The University Of Texas System Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
EP3390449A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antibodies to risperidone and use thereof
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CN119505006A (zh) * 2024-11-14 2025-02-25 杭州旭科生物技术有限公司 抗喹硫平的抗体或其抗原结合片段及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030202975A1 (en) * 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
US20040127489A1 (en) * 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
US20080260812A1 (en) * 2004-04-26 2008-10-23 Takami Matsuyama C/O Kagoshima University Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta)

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
DE3856421T2 (de) 1987-04-27 2000-12-14 Unilever Nv Spezifische Bindungstestverfahren
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
PT582368E (pt) 1992-05-29 2001-05-31 Lilly Co Eli Derivados de tienobenzodiazepina para o tratamento de doencas de cns
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
AU710106B2 (en) 1994-06-10 1999-09-16 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
CA2479932A1 (en) 2002-03-28 2003-10-09 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
ATE361289T1 (de) 2002-08-05 2007-05-15 Lilly Co Eli Piperazinsubstituierte arylbenzodiazepine
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
PL1658277T3 (pl) 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
US7863441B2 (en) 2003-09-23 2011-01-04 Fermion Oy Preparation of quetiapine
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
ATE449337T1 (de) 2003-12-12 2009-12-15 Inverness Medical Switzerland Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
WO2008050341A2 (en) 2006-10-25 2008-05-02 Ramot At Tel-Aviv University Ltd Novel psychotropic agents having glutamate nmda activity
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
CN101091700B (zh) 2007-07-03 2011-06-08 上海现代药物制剂工程研究中心有限公司 富马酸喹硫平缓控释制剂组合物及其制备用途
US8076160B2 (en) 2007-09-27 2011-12-13 Novartis Ag Drug monitoring assay
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
UY32174A (es) 2008-10-14 2010-05-31 Astrazeneca Ab Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
CA2742074A1 (en) 2008-10-29 2010-08-26 Janssen Pharmaceutica Nv Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
EP2389169A1 (en) 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
CA2882038A1 (en) 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
CN104837838A (zh) 2012-08-21 2015-08-12 詹森药业有限公司 帕潘立酮半抗原
PL2888257T3 (pl) 2012-08-21 2018-02-28 Janssen Pharmaceutica Nv Hapteny kwetiapiny do zastosowania w testach immunologicznych
PL2888592T3 (pl) * 2012-08-21 2018-03-30 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
WO2014031656A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to olanzapine haptens and use thereof
JP2015527365A (ja) 2012-08-21 2015-09-17 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンに対する抗体及びその使用
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
CN104854110B (zh) 2012-08-21 2016-12-28 詹森药业有限公司 奥氮平半抗原
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
JP6450314B2 (ja) 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
ES2691092T3 (es) 2012-08-21 2018-11-23 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
CA2882596C (en) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Antibodies to olanzapine and use thereof
ES2669565T3 (es) 2012-08-21 2018-05-28 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
JP6131414B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールのハプテン及びイムノアッセイにおけるそれらの使用
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US10435478B2 (en) * 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030202975A1 (en) * 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
US20040127489A1 (en) * 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
US20080260812A1 (en) * 2004-04-26 2008-10-23 Takami Matsuyama C/O Kagoshima University Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Enzyme Immunoassay for the Detection of Olanzapine in Urine or Serum;Gentaur;《data sheet》;20120505;第1-6页 *

Also Published As

Publication number Publication date
EP3333195B1 (en) 2020-08-05
ES2822004T3 (es) 2021-04-28
JP6843936B2 (ja) 2021-03-17
US20140057306A1 (en) 2014-02-27
AU2018202554B2 (en) 2020-04-30
WO2014031668A3 (en) 2014-04-24
US9410972B2 (en) 2016-08-09
PL2888592T3 (pl) 2018-03-30
US10288631B2 (en) 2019-05-14
CA2882615A1 (en) 2014-02-27
JP2015527368A (ja) 2015-09-17
JP6242893B2 (ja) 2017-12-06
JP6588069B2 (ja) 2019-10-09
CN106928369B (zh) 2021-04-02
CN106928369A (zh) 2017-07-07
EP2888592B1 (en) 2017-11-08
AU2013305907A1 (en) 2015-03-05
US20190271712A1 (en) 2019-09-05
CA2882615C (en) 2019-07-09
CN104755929A (zh) 2015-07-01
EP2888592A4 (en) 2016-05-11
PL3333195T3 (pl) 2021-02-22
AU2018202554A1 (en) 2018-05-10
HK1212035A1 (en) 2016-06-03
EP2888592A2 (en) 2015-07-01
US20160341749A1 (en) 2016-11-24
WO2014031668A2 (en) 2014-02-27
JP2020063232A (ja) 2020-04-23
HK1255219A1 (en) 2019-08-09
AU2013305907B2 (en) 2018-01-18
EP3333195A1 (en) 2018-06-13
ES2654413T3 (es) 2018-02-13
JP2018076317A (ja) 2018-05-17
PT3333195T (pt) 2020-10-12
PT2888592T (pt) 2018-01-29

Similar Documents

Publication Publication Date Title
CN104755929B (zh) 喹硫平的抗体及其用途
CN104737017B (zh) 利培酮的抗体及其用途
CN104755928B (zh) 奥氮平的抗体及其用途
CN104755631B (zh) 阿立哌唑的抗体及其用途
CN104736561B (zh) 帕潘立酮的抗体及其用途
JP6949025B2 (ja) リスペリドンに対する抗体及びその使用
JP2019504014A (ja) クエチアピンに対する抗体及びその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20161223

Address after: Belgium. Beals was Hot Springs Road No. 30.

Patentee after: JANSSEN PHARMACEUTICA N.V.

Address before: New jersey, USA

Patentee before: Ortho-Clinical Diagnostics, Inc.

Patentee before: JANSSEN PHARMACEUTICA N.V.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161109